Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evidence suggests that repeated or chronic ketamine use, as compared to acute ketamine users, posed a higher clinical risk of developing psychotic disorders, potentially related to the underlying chronic N-methyl-D-aspartate receptor (NMDAR) dysfunction, and a higher risk of suffering from schizophrenia particularly in those genetically susceptible, or genetically predisposed ketamine abusers. With ketamine infusion rises as a emerging hope as an acute treatment for depression and suicidality under the shadow of unknown longer term psychotomimetic effects peculiarly amongst repeated or chronic use, the current case-control study aims to investigate: a) if repeated or chronic ketamine use is associated with an increased risk of psychosis by comparing those ketamine abusers with and without psychosis, and to those non-ketamine-using drug abusers with psychosis; and b) if genetic predisposition from single nucleotide polymorphisms are associated with risk of psychosis in ketamine abusers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Case | Ketamine user with psychotic disorders |
| |
| Control Group 1 | Ketamine user without psychotic disorders |
| |
| Control Group 2 | Non-ketamine-using drug user with psychotic disorders |
| |
| Control Group 3 | Non-ketamine-using drug user without psychotic disorders ( identified from register-based medical record system) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| genome testing | Diagnostic Test | blood sampling via venipuncture |
|
| Measure | Description | Time Frame |
|---|---|---|
| relative risk of ketamine users compared to non-ketamine using drug user to develop psychosis | relative risk of ketamine users compared to non-ketamine using drug user to develop psychosis | During the 2 year study period |
| Measure | Description | Time Frame |
|---|---|---|
| Gene association to development of psychcosis | The single nucleotide polymorphism of 4 genes associated with N-methyl-D-aspartate and dopamine receptors being associated with the development of psychosis in ketamine abuser | During the 2 year study period |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
ketamine abuser and non-ketamine-using drug abusers
Not provided
| Name | Affiliation | Role |
|---|---|---|
| albert KK Chung, MBBS(HK) | The University of Hong Kong | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Queen Mary Hospital | Hong Kong | 000000 | Hong Kong | |||
| Western Psychiatric Centre |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Nov 3, 2022 | |
| Reset | Sep 13, 2023 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Nov 3, 2022 | Sep 13, 2023 |
| ID | Term |
|---|---|
| D011618 | Psychotic Disorders |
| D019966 | Substance-Related Disorders |
| D012559 | Schizophrenia |
| D020022 | Genetic Predisposition to Disease |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
| D064419 | Chemically-Induced Disorders |
| D004198 | Disease Susceptibility |
Not provided
Not provided
Not provided
Not provided
Not provided
| Hong Kong |
| 00000 |
| Hong Kong |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |